Knighton Kelson, Babun Asis, Turney James, Evans Brehyn, Sehgal Inder
Department of Biomedical Sciences, Rocky Vista University, Ivins, UT 84738, USA.
Med Sci (Basel). 2025 Aug 20;13(3):148. doi: 10.3390/medsci13030148.
Pirfenidone (PFD) is a pyridine-like compound most well-known for its use in idiopathic pulmonary fibrosis (IPF). However, its broad anti-inflammatory and anti-fibrotic actions make PFD a candidate for other scarring diseases. This review examines the use of PFD for dermatologic conditions. The literature supports the potential for PFD to decrease scarring in a variety of skin conditions. Both oral and topical preparations have been shown to be effective at aiding skin healing. Early clinical evidence demonstrates significant improvements in hypertrophic burn scars, reduction in fibrosis in localized scleroderma, and accelerated epithelialization of skin graft donor sites. These clinical outcomes are supported by PFD's modulation of the transforming growth factor-beta (TGF-β) pathway, which plays a central role in skin fibrosis and scarring. Evidence in this review suggests topical PFD can be used to fill a clinical need for local anti-fibrotic therapies.
吡非尼酮（PFD）是一种吡啶类化合物，因其在特发性肺纤维化（IPF）中的应用而最为人所知。然而，其广泛的抗炎和抗纤维化作用使PFD成为其他瘢痕形成疾病的候选药物。本综述探讨了PFD在皮肤病中的应用。文献支持PFD在多种皮肤疾病中减少瘢痕形成的潜力。口服和外用制剂均已显示出有助于皮肤愈合的效果。早期临床证据表明，肥厚性烧伤瘢痕有显著改善，局限性硬皮病的纤维化减轻，皮肤移植供区的上皮化加速。这些临床结果得到了PFD对转化生长因子-β（TGF-β）通路调节的支持，该通路在皮肤纤维化和瘢痕形成中起核心作用。本综述中的证据表明，外用PFD可用于满足局部抗纤维化治疗的临床需求。
